PHI with Hanot-MacMahon-Tannhäuser Syndrome
How does this condition affect your private health insurance?
Hanot-Macmahon-Tannhaeuser-Syndrom, more commonly known as Primary Biliary Cholangitis (PBC), is a chronic, autoimmune liver disease characterized by the progressive destruction of small bile ducts within the liver. This destruction leads to cholestasis, where bile cannot flow out of the liver, causing bile acids to accumulate and damage liver cells. Over time, this can lead to fibrosis, cirrhosis, and ultimately liver failure. Symptoms often include fatigue, pruritus (itching), dry eyes and mouth, and abdominal discomfort. It predominantly affects women. Early diagnosis and treatment, typically with ursodeoxycholic acid, are crucial to slow disease progression and prevent severe complications, though a cure is not yet available.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Months to several years for initial symptoms to manifest and be diagnosed.
Duration of Illness (Lifetime)
Lifelong, chronic progressive disease.
Cost of Treatment (Initial)
Moderate to high (diagnostic tests, specialist consultations, initial medication).
Cost of Treatment (Lifetime)
High to very high (lifelong medication, regular monitoring, complication management, potential liver transplant).
Mortality Rate
Low to moderate with timely treatment, significantly higher without treatment or in advanced stages.
Risk of Secondary Damages
Very high (cirrhosis, liver failure, portal hypertension, osteopenia, severe fatigue, pruritus, other autoimmune conditions).
Probability of Full Recovery
Very low; management focuses on slowing progression, not cure.
Underlying Disease Risk
High (e.g., Sjogren's syndrome, autoimmune thyroiditis, rheumatoid arthritis, celiac disease).